CR20120604A - Formulación de liberación sostenida - Google Patents

Formulación de liberación sostenida

Info

Publication number
CR20120604A
CR20120604A CR20120604A CR20120604A CR20120604A CR 20120604 A CR20120604 A CR 20120604A CR 20120604 A CR20120604 A CR 20120604A CR 20120604 A CR20120604 A CR 20120604A CR 20120604 A CR20120604 A CR 20120604A
Authority
CR
Costa Rica
Prior art keywords
sustained release
release formulation
salts
average molecular
relates
Prior art date
Application number
CR20120604A
Other languages
English (en)
Inventor
Tomomichi Futo
Hikaru Taira
Seitaro Mizukami
Naoyuki Murata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120604(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20120604A publication Critical patent/CR20120604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/005—Processes for mixing polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una formulación de liberación sostenida que comprende un derivado de metastina y un polímero láctico que tiene un peso molecular medio en peso de aproximadamente 5000 a aproximadamente 40000 o una de sus sales.
CR20120604A 2010-06-25 2012-11-29 Formulación de liberación sostenida CR20120604A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010144792 2010-06-25

Publications (1)

Publication Number Publication Date
CR20120604A true CR20120604A (es) 2013-03-21

Family

ID=44583663

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120604A CR20120604A (es) 2010-06-25 2012-11-29 Formulación de liberación sostenida

Country Status (25)

Country Link
US (2) US20130210742A1 (es)
EP (1) EP2585091B1 (es)
JP (1) JP5838173B2 (es)
KR (1) KR20130097088A (es)
CN (1) CN103025343B (es)
AR (1) AR081980A1 (es)
AU (1) AU2011270093A1 (es)
BR (1) BR112012032544A2 (es)
CA (1) CA2802209C (es)
CL (1) CL2012003645A1 (es)
CR (1) CR20120604A (es)
DO (1) DOP2012000304A (es)
EA (1) EA021663B1 (es)
EC (1) ECSP12012350A (es)
ES (1) ES2513569T3 (es)
IL (1) IL223266A0 (es)
MA (1) MA34321B1 (es)
MX (1) MX2012014265A (es)
PE (1) PE20130276A1 (es)
PH (1) PH12012502548A1 (es)
SG (1) SG186070A1 (es)
TN (1) TN2012000562A1 (es)
TW (1) TW201204378A (es)
UY (1) UY33465A (es)
WO (1) WO2011162413A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TWI778979B (zh) 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 治療女性不孕症之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
WO2002085399A1 (fr) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
ZA200902452B (en) * 2006-10-25 2010-07-28 Takeda Pharmaceutical Metastin derivatives and use thereof
MX2009006653A (es) * 2006-12-18 2009-07-02 Takeda Pharmaceutical Composicion de liberacion prolongada y metodo para producirla.
EP2277900A4 (en) * 2008-04-24 2011-08-03 Takeda Pharmaceutical METASTINE DERIVATIVE AND ITS USE
JP2012513982A (ja) * 2008-12-29 2012-06-21 武田薬品工業株式会社 癌の予防・治療剤
CN102665690A (zh) * 2009-12-22 2012-09-12 武田药品工业株式会社 缓释制剂

Also Published As

Publication number Publication date
AU2011270093A1 (en) 2013-01-10
CN103025343B (zh) 2015-03-25
WO2011162413A1 (en) 2011-12-29
EP2585091A1 (en) 2013-05-01
IL223266A0 (en) 2013-02-03
EP2585091B1 (en) 2014-09-10
CA2802209C (en) 2019-12-31
ES2513569T3 (es) 2014-10-27
CA2802209A1 (en) 2011-12-29
PE20130276A1 (es) 2013-03-20
JP5838173B2 (ja) 2016-01-06
UY33465A (es) 2012-01-31
BR112012032544A2 (pt) 2016-10-11
TN2012000562A1 (en) 2014-04-01
AR081980A1 (es) 2012-10-31
CL2012003645A1 (es) 2013-04-05
JP2013530926A (ja) 2013-08-01
ECSP12012350A (es) 2014-02-28
EA021663B1 (ru) 2015-08-31
SG186070A1 (en) 2013-01-30
MX2012014265A (es) 2013-01-18
US20130210742A1 (en) 2013-08-15
DOP2012000304A (es) 2013-01-31
MA34321B1 (fr) 2013-06-01
PH12012502548A1 (en) 2013-02-11
TW201204378A (en) 2012-02-01
KR20130097088A (ko) 2013-09-02
CN103025343A (zh) 2013-04-03
EA201291303A1 (ru) 2013-04-30
US20180243422A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
CY1119060T1 (el) Ρυθμιστες ενζυμων μεθυλικης τροποποιησης, συνθεσεις και χρησεις αυτων
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
UY33504A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
AR080147A1 (es) Polimeros colorantes
PA8774501A1 (es) Nueva sales y sus usos
GT201200284A (es) Composición farmacéutica
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR077237A1 (es) Polimeros colorantes
BR112013003388A2 (pt) sal de besilato de um inibidor de btk
CR20150120A (es) Nuevos derivados bicíclicos
MA32939B1 (fr) Composes organiques
AR077047A1 (es) Polimeros colorantes cationicos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
GT200900315A (es) Inhibición de arni de expresión de alfa-enac
EP2820174A4 (en) PROCESS AND USE FOR MOLECULAR TAGS
BR112013007362A2 (pt) composição farmacêutica
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
MX2013006644A (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
CY1117491T1 (el) Μεθοδος για την παρασκευη 2-(2,3-διμεθυλφαινυλ)-1-προπαναλης με χλωροακετονη
BR112013033557A2 (pt) aditivo adesivo
CY1120597T1 (el) Νεα χρηση
CY1121696T1 (el) Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)